- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: August 2017
- Public Summary Document (PSD) August 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) August 2017 PBAC Meeting - Word
Pembrolizumab (rrchl) – August 2017
Pembrolizumab (rrcHL), powder for I.V. infusion, 50 mg and 100 mg vials, Keytruda®
Last updated
13 July 2018